We are focused on the development of high-quality products and services that drive novel discovery and contribute to improving human health. Here is a sampling of publications by our scientists using the Oncomine™ Platform. 

1. The mutational landscape of lethal castration-resistant prostate cancer
Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett MJ, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA
Nature | Letter Published online 20 May 2012 | Link

2. Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance.
Lupien M, Meyer CA, Bailey ST, Eeckhoute J, Cook J, Westerling T, Zhang X, Carroll JS, Rhodes DR, Liu XS, Brown M.
Genes Dev. 2010 Oct 1;24(19):2219-27. | Pubmed

3. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival.
Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, Settleman J.
Cancer Cell. 2009 Jun 2;15(6):489-500. | Pubmed

4. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist.
Rhodes DR, Ateeq B, Cao Q, Tomlins SA, Mehra R, Laxman B, Kalyana-Sundaram S, Lonigro RJ, Helgeson BE, Bhojani MS, Rehemtulla A, Kleer CG, Hayes DF, Lucas PC, Varambally S, Chinnaiyan AM.
Proc Natl Acad Sci U S A. 2009 Jun 1. [Epub ahead of print]. | Pubmed

5. Exploring clinical associations using ‘-omics’ based enrichment analyses.
Hanauer DA, Rhodes DR, Chinnaiyan AM.
PLoS ONE. 2009;4(4):e5203. Epub 2009 Apr 13. | Pubmed

6. Coactivator function defines the active estrogen receptor-{alpha} cistrome.
Lupien M, Eeckhoute J, Meyer CA, Krum SA, Rhodes DR, Liu XS, Brown M.
Mol Cell Biol. 2009 Apr 13. [Epub ahead of print] | Pubmed

7. The role of SPINK1 in ETS rearrangement-negative prostate cancers.
Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F, Helgeson BE, Laxman B, Morris DS, Cao Q, Cao X, Andrén O, Fall K, Johnson L, Wei JT, Shah RB, Al-Ahmadie H, Eastham JA, Eggener SE, Fine SW, Hotakainen K, Stenman UH, Tsodikov A, Gerald WL, Lilja H, Reuter VE, Kantoff PW, Scardino PT, Rubin MA, Bjartell AS, Chinnaiyan AM.
Cancer Cell. 2008 Jun;13(6):519-28. | Pubmed

8. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.
Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andrén O, Johnson LA, Tang J, Adami HO, Calza S, Chinnaiyan AM, Rhodes D, Tomlins S, Fall K, Mucci LA, Kantoff PW, Stampfer MJ, Andersson SO, Varenhorst E, Johansson JE, Brown M, Golub TR, Rubin MA.
J Natl Cancer Inst. 2008 Jun 4;100(11):815-25. Epub 2008 May 27. | Pubmed

9. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.
Yu J, Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, Mehra R, Wang X, Ghosh D, Shah RB, Varambally S, Pienta KJ, Chinnaiyan AM.
Cancer Res. 2007 Nov 15;67(22):10657-63. | Pubmed

10. Identifying significant associations using free text problem summary lists in a clinical data repository.
Hanauer DA, Rhodes DR, Chinnaiyan AM.
AMIA Annu Symp Proc. 2007 Oct 11:968. | Pubmed

11. Molecular concepts analysis links tumors, pathways, mechanisms, and drugs.
Rhodes DR, Kalyana-Sundaram S, Tomlins SA, Mahavisno V, Kasper N, Varambally R, Barrette TR, Ghosh D, Varambally S, Chinnaiyan AM.
Neoplasia. 2007 May;9(5):443-54. | Pubmed

12. Integrating biomedical knowledge to model pathways of prostate cancer progression.
Morris DS, Tomlins SA, Rhodes DR, Mehra R, Shah RB, Chinnaiyan AM.
Cell Cycle . 2007 May;6(10):1177-87. | Pubmed

13. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles.
Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varmbally R, Yu J, Briggs BB, Barrette TR, Anstett MJ, Kincaid-Beal C, Kulkarni P, Varambally S, Ghosh D, Chinnaiyan AM.
Neoplasia. 2007 Feb;9(2):166-80. | Pubmed

14. Bioinformatics approaches in the study of cancer.
Hanauer DA, Rhodes DR, Sinha-Kumar C, Chinnaiyan AM.
Curr Mol Med. 2007 Feb;7(1):133-41. Review. | Pubmed

15. Integrative molecular concept modeling of prostate cancer progression.
Scott A Tomlins, Rohit Mehra, Daniel R Rhodes, Xuhong Cao, Lei Wang, Saravana M Dhanasekaran, Shanker Kalyana-Sundaram, John T Wei, Mark A Rubin, Kenneth J Pienta, Rajal B Shah & Arul M Chinnaiyan.
Nature Genetics 2007 Jan.; 39, 41 - 51 | Pubmed

16. Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation.
Giordano TJ, Au AYM, Kuick R, Thomas DG, Rhodes DR, Wilhelm KG, Vinco M, Misek DE, Sanders D, Zhu ZW, Ciampi R, Hanash S, Chinnaiyan A, Clifton-Bligh RJ, Robinson BG, Nikiforov YE, Koenig RJ.
Clinical Cancer Research 2006 Apr 1;12(7 Pt 1):1983-93. | Pubmed

17. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.
Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, Cao X, Wei JT, Rubin MA, Shah RB, Chinnaiyan AM.
Cancer Res. 2006 Apr 1;66(7):3396-400. | Pubmed

18. Whole transcriptome amplification for gene expression profiling and development of molecular archives.
Tomlins SA, Mehra R, Rhodes DR, Shah RB, Rubin MA, Bruening E, Makarov V, Chinnaiyan AM.
Neoplasia. 2006 Feb;8(2):153-62. | Pubmed

19. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer.
Fu Z, Kitagawa Y, Shen R, Shah R, Mehra R, Rhodes D, Keller PJ, Mizokami A, Dunn R, Chinnaiyan AM, Yao Z, Keller ET.
Prostate. 2006 Feb 15;66(3):248-56. | Pubmed

20. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.
Varambally S, Yu JJ, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM.
Cancer Cell. 2005 Nov;8(5):393-406. | Pubmed

21. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM.
Science 2005 Oct 28;310(5748):644-8. | Pubmed

22. Probabilistic model of the human protein-protein interaction network.
Rhodes DR, Tomlins SA, Varambally S, Mahavisno V, Barrette T, Kalyana-Sundaram S, Ghosh D, Pandey A, Chinnaiyan AM.
Nat Biotechnology. 2005 Aug; 23(8):951-9 | Pubmed

23. Integrative analysis of the cancer transcriptome.
Rhodes DR, Chinnaiyan AM.
Nat Genet. 2005 Jun;37 Suppl:S31-7. Review. | Pubmed

24. Mining for regulatory programs in the cancer transcriptome.
Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Barrette TR, Ghosh D, Chinnaiyan AM.
Nat Genet. 2005 Jun; 37(6):579-83. | Pubmed

25. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression.
Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM.
PNAS 2004 Jun 22;101(25):9309-14. | Pubmed

26. Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer.
Rubin MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL, Hofer MD, Storz-Schweizer M, Kuefer R, Fletcher JA, Hsi BL, Byrne JA, Pienta KJ, Collins C, Sellers WR, Chinnaiyan AM.
Cancer Res. 2004 Jun; 64 (11): 3814-3822. | Pubmed

27. Bioinformatics strategies for translating genome-wide expression analyses into clinically useful cancer markers.
Rhodes DR, Chinnaiyan AM.
Ann N Y Acad Sci. 2004 May;1020:32-40. Review. | Pubmed

28. Oncomine: a cancer microarray database and data-mining platform.
Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM.
Neoplasia 2004 Jan-Feb; 6(1):1-6 | Pubmed

29. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer.
Sreekumar A, Laxman B, Rhodes DR, Bhagavathula S, Harwood J, Giacherio D, Ghosh D, Sanda MG, Rubin MA, Chinnaiyan AM.
J Natl Cancer Inst. 2004 Jun 2;96(11):834-43. Erratum in: J Natl Cancer Inst. 2004 Jul 21;96(14):1112. | Pubmed

30. Prostate cancer biomarkers: a current perspective.
Kumar-Sinha C, Rhodes DR, Yu J, Chinnaiyan AM.
Expert Rev Mol Diagn. 2003 Jul;3(4):459-70. Review. | Pubmed

31. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer.
Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA.
J Natl Cancer Inst. 2003 May 7;95(9):661-8. | Pubmed

32. Dysregulation of the annexin family protein family is associated with prostate cancer progression.
Xin W, Rhodes DR, Ingold C, Chinnaiyan AM, Rubin MA.
Am J Pathol. 2003 Jan;162(1):255-61. | Pubmed

33. DNA microarrays: implications for clinical medicine.
Rhodes DR, Chinnaiyan AM.
J Invest Surg. 2002 Sep-Oct;15(5):275-9. Review. | Pubmed

34. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer.
Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM.
Cancer Res. 2002 Aug 1;62(15):4427-33. | Pubmed

35. CIT: identification of differentially expressed clusters of genes from microarray data.
Rhodes DR, Miller JC, Haab BB, Furge KA.
Bioinformatics. 2002 Jan;18(1):205-6. | Pubmed

36. Cyclophilin B expression is associated with in vitro radioresistance and clinical outcome after radiotherapy.
Williams PD, Owens CR, Dziegielewski J, Moskaluk CA, Read PW, Larner JM, Story MD, Brock WA, Amundson SA, Lee JK, Theodorescu D.
Neoplasia. 2011 Dec;13(12):1122-31. | Pubmed

37. Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer.
Thomas S, Overdevest JB, Nitz MD, Williams PD, Owens CR, Sanchez-Carbayo M, Frierson HF, Schwartz MA, Theodorescu D.
Cancer Res. 2011 Feb 1;71(3):832-41. | Pubmed

38. Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy.
Williams PD, Cheon S, Havaleshko DM, Jeong H, Cheng F, Theodorescu D, Lee JK.
Cancer Res. 2009 Nov 1;69(21):8302-9. | Pubmed

39. Genomancy: predicting tumour response to cancer therapy based on the oracle of genetics.
Williams PD, Lee JK, Theodorescu D.
Curr Oncol. 2009 Jan;16(1):56-8. | Pubmed

40. Molecular credentialing of rodent bladder carcinogenesis models.
Williams PD, Lee JK, Theodorescu D.
Neoplasia. 2008 Aug;10(8):838-46. | Pubmed

41. 5-(2-Pyrimidinyl)-imidazo[1,2-a]pyridines are antibacterial agents targeting the ATPase domains of DNA gyrase and topoisomerase IV.
Starr JT, Sciotti RJ, Hanna DL, Huband MD, Mullins LM, Cai H, Gage JW, Lockard M, Rauckhorst MR, Owen RM, Lall MS, Tomilo M, Chen H, McCurdy SP, Barbachyn MR.
Bioorg Med Chem Lett. 2009 Sep 15;19(18):5302-6. | Pubmed

42. Streptococcus pneumononiae gyrase ATPase: development and validation of an assay for inhibitor discovery and characterization.
Miller JR, Herberg JT, Tomilo M, McCroskey MC, Feilmeier BJ.
Anal Biochem. 2007 Jun 1;365(1):132-43. | Pubmed

43. Purification and characterization of recombinant Staphylococcus haemolyticus DNA gyrase and topoisomerase IV expressed in Escherichia coli.
Bronstein JC, Olson SL, LeVier K, Tomilo M, Weber PC.
Antimicrob Agents Chemother. 2004 Jul;48(7):2708-11. | Pubmed

44. Monoclonal antibodies against macrophage colony-stimulating factor diminish the number of circulating intermediate and nonclassical (CD14(++)CD16(+)/CD14(+)CD16(++)) monocytes in rheumatoid arthritis patient.
Korkosz M, Bukowska-Strakova K, Sadis S, Grodzicki T, Siedlar M.
Blood. 2012 May 31;119(22):5329-30. | Pubmed

45. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, Connell CA, Gruben D, Krishnaswami S, Wallenstein G, Wilkinson BE, Zwillich SH.
Arthritis Rheum. 2012 Mar;64(3):617-29. | Pubmed

46. Increased serum enzyme levels associated with kupffer cell reduction with no signs of hepatic or skeletal muscle injury.
Radi ZA, Koza-Taylor PH, Bell RR, Obert LA, Runnels HA, Beebe JS, Lawton MP, Sadis S.
Am J Pathol. 2011 Jul;179(1):240-7. | Pubmed

47. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.
Marzec M, Kasprzycka M, Lai R, Gladden AB, Wlodarski P, Tomczak E, Nowell P, Deprimo SE, Sadis S, Eck S, Schuster SJ, Diehl JA, Wasik MA.
Blood. 2006 Sep 1;108(5):1744-50. | Pubmed

48. Complementary whole-genome technologies reveal the cellular response to proteasome inhibition by PS-341.
Fleming JA, Lightcap ES, Sadis S, Thoroddsen V, Bulawa CE, Blackman RK.
Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1461-6. | Pubmed

49. Herpes simplex virus type 1 immediate-early protein ICP0 and is isolated RING finger domain act as ubiquitin E3 ligases in vitro.
Boutell C, Sadis S, Everett RD.
J Virol. 2002 Jan;76(2):841-50. | Pubmed

50. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H, Bridges E, Shi W, Snell C, Bowden ET, Wu H, Chowdhury PS, Russell AJ, Montgomery CP, Poulsom R, Harris AL.
Cancer Res. 2011 Sep 15;71(18):6073-83. | Pubmed

51. E6AP mediates regulated proteasomal degradation of the nuclear receptor coactivator amplified in breast cancer 1 in immortalized cells.
Mani A, Oh AS, Bowden ET, Lahusen T, Lorick KL, Weissman AM, Schlegel R, Wellstein A, Riegel AT.
Cancer Res. 2006 Sep 1;66(17):8680-6. | Pubmed

52. Co-localization of cortactin and phosphotyrosine identifies active invadopodia in human breast cancer cells.
Bowden ET, Onikoyi E, Slack R, Myoui A, Yoneda T, Yamada KM, Mueller SC.
Exp Cell Res. 2006 May 1;312(8):1240-53. | Pubmed

53. Expression of a fibroblast growth factor-binding protein during the development of adenocarcinoma of the pancreas and colon.
Tassi E, Henke RT, Bowden ET, Swift MR, Kodack DP, Kuo AH, Maitra A, Wellstein A.
Cancer Res. 2006 Jan 15;66(2):1191-8. | Pubmed

54. Identification of the fibroblast growth factor (FGF)-interacting domain in a secreted FGF-binding protein by phage display.
Xie B, Tassi E, Swift MR, McDonnell K, Bowden ET, Wang S, Ueda Y, Tomita Y, Riegel AT, Wellstein A.
J Biol Chem. 2006 Jan 13;281(2):1137-44. | Pubmed

55. Surface expression and CEA binding of hnRNP M4 protein in HT29 colon cancer cells.
Laguinge L, Bajenova O, Bowden E, Sayyah J, Thomas P, Juhl H.
Anticancer Res. 2005 Jan-Feb;25(1A):23-31. | Pubmed

56. Vascular leakage in chick embryos after expression of a secreted binding protein for fibroblast growth factors.
McDonnell K, Bowden ET, Cabal-Manzano R, Hoxter B, Riegel AT, Wellstein A.
Lab Invest. 2005 Jun;85(6):747-55. | Pubmed

57. Tetracycline-regulated expression of hammerhead ribozymes in vivo.
Bowden ET, Riegel AT.
Methods Mol Biol. 2004;252:179-94. | Pubmed

58. Structure and function of human Vps20 and Snf7 proteins.
Peck JW, Bowden ET, Burbelo PD.
Biochem J. 2004 Feb 1;377(Pt 3):693-700. | Pubmed

59. The RhoA-binding protein, rhophilin-2, regulates actin cytoskeleton organization.
Peck JW, Oberst M, Bouker KB, Bowden E, Burbelo PD.
J Biol Chem. 2002 Nov 15;277(46):43924-32. | Pubmed

60. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types.
Stoica GE, Kuo A, Powers C, Bowden ET, Sale EB, Riegel AT, Wellstein A.
J Biol Chem. 2002 Sep 27;277(39):35990-8. | Pubmed

61. Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase.
Bowden ET, Stoica GE, Wellstein A.
J Biol Chem. 2002 Sep 27;277(39):35862-8. | Pubmed

62. The RhoA-binding protein, rhophilin-2, regulates actin cytoskeleton organization.
Peck JW, Oberst M, Bouker KB, Bowden E, Burbelo PD.
J Biol Chem. 2002 Nov 15;277(46):43924-32. | Pubmed

63. Surface expression and CEA binding of hnRNP M4 protein in HT29 colon cancer cells.
Laguinge L, Bajenova O, Bowden E, Sayyah J, Thomas P, Juhl H.
Anticancer Res. 2005 Jan-Feb;25(1A):23-31. | Pubmed

64. A novel Saccharomyces cerevisiae secretory mutant possesses a thermolabile phosphomannose isomerase.
Payton MA, Rheinnecker M, Klig LS, DeTiani M, Bowden E.
J Bacteriol. 1991 Mar;173(6):2006-10. | Pubmed

65. Construction of a computable cell proliferation network focused on non-diseased lung cells.
Westra JW, Schlage WK, Frushour BP, Gebel S, Catlett NL, Han W, Eddy SF, Hengstermann A, Matthews AL, Mathis C, Lichtner RB, Poussin C, Talikka M, Veljkovic E, Van Hooser AA, Wong B, Maria MJ, Peitsch MC, Deehan R, Hoeng J.
BMC Syst Biol. 2011 Jul 2;5:105. | Pubmed

66. The role of hypoxia in 2-butoxyethanol-induced hemangiosarcoma.
Laifenfeld D, Gilchrist A, Drubin D, Jorge M, Eddy SF, Frushour BP, Ladd B, Obert LA, Gosink MM, Cook JC, Criswell K, Somps CJ, Koza-Taylor P, Elliston KO, Lawton MP.
Toxicol Sci. 2010 Jan;113(1):254-66. | Pubmed

67. RelB NF-kappaB represses estrogen receptor alpha expression via induction of the zinc finger protein Blimp1.
Wang X, Belguise K, O'Neill CF, Sánchez-Morgan N, Romagnoli M, Eddy SF, Mineva ND, Yu Z, Min C, Trinkaus-Randall V, Chalbos D, Sonenshein GE.
Mol Cell Biol. 2009 Jul;29(14):3832-44. | Pubmed

68. NF-kappaB and epithelial to mesenchymal transition of cancer.
Min C, Eddy SF, Sherr DH, Sonenshein GE.
J Cell Biochem. 2008 Jun 1;104(3):733-44. Review. | Pubmed

69. Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate.
Eddy SF, Kane SE, Sonenshein GE.
Cancer Res. 2007 Oct 1;67(19):9018-23. | Pubmed

70. Inducible IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells.
Eddy SF, Guo S, Demicco EG, Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE.
Cancer Res. 2005 Dec 15;65(24):11375-83. | Pubmed

71. Host regulatory network response to infection with highly pathogenic H5N1 avian influenza virus.
Li C, Bankhead A 3rd, Eisfeld AJ, Hatta Y, Jeng S, Chang JH, Aicher LD, Proll S, Ellis AL, Law GL, Waters KM, Neumann G, Katze MG, McWeeney S, Kawaoka Y.
J Virol. 2011 Nov;85(21):10955-67. | Pubmed

72. Knowledge based identification of essential signaling from genome-scale siRNA experiments.
Bankhead A 3rd, Sach I, Ni C, LeMeur N, Kruger M, Ferrer M, Gentleman R, Rohl C.
BMC Syst Biol. 2009 Aug 5;3:80. | Pubmed

73. Cellular automaton simulation examining progenitor hierarchy structure effects on mammary ductal carcinoma in situ.
Bankhead A 3rd, Magnuson NS, Heckendorn RB.
J Theor Biol. 2007 Jun 7;246(3):491-8. | Pubmed

74. Gene knockout experiments to quantify a G2/M genetic network simulation for mammary cancer susceptibility.
Bankhead A 3rd, Magnuson NS, Heckendorn RB.
In Silico Biol. 2006;6(3):181-92. | Pubmed